SCHEMBL4262200

SCHEMBL4262200

CC(=O)C(Sc1ccccc1)c1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.66
SMN1; SMN2 Q16637 2/20 0.60
PKM P14618 1/20 0.60
MAPT P10636 4/20 0.59
ALDH1A1 P00352 3/20 0.55
GAA P10253 2/20 0.55
L3MBTL1 Q9Y468 2/20 0.55
KDM4E B2RXH2 1/20 0.55
PAX8 Q06710 1/20 0.54
MAPK1 P28482 1/20 0.51
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
TDP1 Q9NUW8 1/20 0.51
CNR1 P21554 1/20 0.51
POLB P06746 1/20 0.50
EPHX1 P07099 1/20 0.49
NPSR1 Q6W5P4 1/20 0.48
TSHR P16473 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6077411 0.88 LMNA (0.53) LMNASMN1; SMN2PKMMAPTALDH1A1
SCHEMBL8132437 0.85 MAPT (0.54) LMNASMN1; SMN2PKMMAPTALDH1A1
SCHEMBL645517 0.83 LMNA (0.65) LMNASMN1; SMN2PKMMAPTALDH1A1
SCHEMBL6796251 0.80 EPHX1 (0.71) LMNASMN1; SMN2PKMMAPTALDH1A1
SCHEMBL934473 0.80 LMNA (0.61) LMNASMN1; SMN2PKMMAPTALDH1A1
SCHEMBL11563692 0.79 SMN1; SMN2 (0.69) LMNASMN1; SMN2PKMMAPTALDH1A1
SCHEMBL20540763 0.79 LMNA (0.65) LMNASMN1; SMN2PKMMAPTALDH1A1
SCHEMBL10882291 0.78 LMNA (0.59) LMNASMN1; SMN2PKMMAPTALDH1A1
SCHEMBL2846675 0.77 LMNA (0.72) LMNASMN1; SMN2PKMMAPTALDH1A1
SCHEMBL7829386 0.76 LMNA (0.56) LMNASMN1; SMN2PKMMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2134683-A2 NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION Intermune, Inc. (US) 2009-12-23 EP disclosed
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-02-19 US disclosed
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-02-19 US disclosed
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-02-19 US disclosed
WO-2008100867-A2 NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2008-08-21 WO disclosed
WO-2008100867-A2 NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2008-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION EIF2AK2, HAVCR2, HCCS LMNA 2969/4885SMN1; SMN2 2901/4885PKM 2067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.